21 results about "Renal cancers" patented technology

The invention discloses a novel HIF-2 alpha proteolysis targeting chimera 1 as well as a preparation method and application thereof, the structural formula 1 of the novel HIF-2 alpha proteolysis targeting chimera 1 is shown in the specification, and the obtained novel HIF-2 alpha proteolysis targeting chimera 1 has good proliferation inhibition activity on kidney cancer 786-O cells. The novel HIF-2alpha protein hydrolysis targeting chimera designed by the invention is novel in structure, few in preparation route process steps, easy to obtain raw materials, suitable for industrial production and good in application value.

Device and methods for detection of kidney cancer using urine samples are disclosed herein. The device and methods enable isolation and quantification of kidney tumor cells in urine samples from a subject in need thereof.

The invention relates to a tumor-related DNA methylation marker combination, which is selected from at least one of the following: a target sequence as shown in SEQ ID NO: 1-SEQ ID NO: 10, a nucleic acid fragment with the length of at least 15 oligonucleotides or a complementary nucleic acid fragment thereof, and the nucleic acid fragment comprises at least one methylation site indicated by CG. The invention also relates to a detection kit for the methylation marker combination. According to the invention, the combination of the co-methylation states of a plurality of specific methylation regions is used for distinguishing and analyzing the occurrence of tumors, especially kidney cancer, the specific methylation combination has high sensitivity for distinguishing the occurrence of kidney cancer, and the detection method is simple, convenient and feasible. The primer pair combination of the kit overcomes the defect of false positive caused by detection mismatch of a single methylation site in the aspect of primer sequence design, and the interaction between a plurality of methylation biomarker primers and probe pair combinations is considered.

The invention provides a method of detecting renal cancer mark- ers in a biological sample from a patient suspected of or to be evaluated for having renal cancer, comprising detecting one or more marker proteins selected from Lipocalin 15, Serum amyloid A1, and Haptoglobin, in the biological sample. The invention further provides a kit suitable for use with the inventive method.

The invention discloses a marker group for screening and diagnosing kidney cancer and application of the marker group, and belongs to the technical field of molecular biology. The marker group comprises at least four of polypeptides as shown in sequences SEQ ID NO. 1 to 38. The marker combination constructed by the invention has more excellent sensitivity and specificity when being used for auxiliary diagnosis and early screening of kidney cancer. The auxiliary diagnosis result of the kit is superior to that of imaging examination which is one of main schemes for clinical diagnosis of kidney tumors at present, and CT is enhanced (the sensitivity and the specificity are 78.67% and 87.88% respectively). The early screening result is superior to that of a high-frequency color Doppler ultrasonic instrument (the diagnosis sensitivity is 94.87%, and the specificity is 80%) which is applied to routine examination of the abdomen in physical examination at present; the sensitivity is 62.9%, and the specificity is 87.0%.

The invention provides a kidney cancer risk grade analysis method based on deep learning. The method comprises the following steps: acquiring multi-modal medical data of a patient and preprocessing the multi-modal medical data to construct a training sample set; training a risk level prediction model by using the sample set until a preset condition is met; inputting data of a to-be-detected patient into the trained model to obtain a predicted risk level, if a low risk threshold is met, suggesting conventional follow-up visit, otherwise, optimizing treatment scheme parameters by adopting a multi-objective optimization algorithm, evaluating the risk level of each scheme through the model, and calculating a fitness function value in combination with a side effect score and a treatment cost; and finally outputting an optimal scheme as a clinical intervention basis. According to the invention, accurate prediction of the risk level of the kidney cancer can be realized, and the accuracy of clinical decision and the benefit-cost ratio of a treatment scheme are improved.

The application discloses a marker group for kidney cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-38.The marker group constructed by the application has more excellent sensitivity and specificity when used for the auxiliary diagnosis and early screening of kidney cancer.The auxiliary diagnosis result is better than that of one of main current clinical diagnosis schemes for kidney tumors, i.e., imaging examination, and enhanced CT (sensitivity and specificity are 78.67% and 87.88%, respectively).The early screening result is better than that of a high-frequency color Doppler ultrasound instrument (diagnostic sensitivity is 94.87%, and specificity is 80%) applied to the routine examination of the abdomen in a health examination; and multi-gene methylation combined analysis (sensitivity is 62.9%, and specificity is 87.0%).

The application belongs to the technical field of medicines, and particularly relates to application of an eight-membered selenium-containing benzazepine compound in preparation of an antitumor drug. The eight-membered selenium-containing benzazepine compound is prepared by an electrochemical method, and the reaction condition is mild and the operation is simple. The compound has certain antitumor and antibacterial activities, and particularly shows good inhibition on renal cancer cells 769-P and A498, and has a good application prospect.

The present disclosure provides methods for treating mesonephric cancers in a subject in need thereof comprising administering a RAF / MEK inhibitor in combination with a FAK inhibitor.

The present disclosure relates generally to compounds of Formulae (1-A), (1-B1), (1-C) and ((1-D) and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder, prostate, or ovarian cancer.

The invention provides a kidney cancer early diagnosis and detection marker combination, application and a kit, and relates to the technical field of biological medicine.In the kidney cancer early diagnosis and detection marker combination, an early kidney cancer marker database is constructed through mass spectrum-based serum proteome analysis, comprehensive marker screening and verification are performed through mass spectrum, machine learning is performed, multiple marker combinations are screened, and the kidney cancer early diagnosis and detection marker combination is obtained. And evaluation is carried out through the internal queue and the external queue to distinguish the early kidney cancer. The biomarkers (RCC-5) of the five proteins are used for distinguishing RCC patients from normal people (RCC vs.NC), and the accuracy rate reaches 95.23%.

The invention provides a metabolic marker composition for distinguishing healthy kidney cancer from early kidney cancer. According to an analysis method based on urine metabonomics, a diagnosis model capable of accurately distinguishing healthy people from early-stage kidney cancer patients is constructed by detecting a specific metabolic marker combination and combining a machine learning algorithm. The model can noninvasively discriminate the early-stage kidney cancer in a high-sensitivity and high-specificity manner, and breaks through the limitation of an existing clinical detection method. The method disclosed by the invention has the advantages of noninvasive property, simple and convenient sampling and the like, is suitable for large-scale population screening, is particularly beneficial to popularization of early-stage kidney cancer risk screening in remote areas deficient in medical resources, and provides support for early-stage noninvasive diagnosis and effective prevention and control of kidney cancer.

The invention provides application of K46 lactic acid of AARS2 mediated ULK1 as a target spot in preparation of an anti-kidney cancer product, so that the K46 lactic acid of the AARS2 mediated ULK1 as the target spot can be used for preparing the anti-kidney cancer product. The use comprises partial or complete knockout of AARS2 and / or ULK1 genes; the AARS2 protein activity is inhibited; the K46 gene of the ULK1 is subjected to specific mutation; the invention relates to a cell penetrating peptide aiming at a ULK1 K46 site and other methods. And inhibiting the expression of AARS2 and / or controlling the K46 lactylation level of ULK1 to play a role in resisting kidney cancer.

The present invention provides: a method of predicting the anticancer drug resistance and / or prognosis in a kidney cancer patient, said method comprising a step for evaluating the expression of Largen in the kidney cancer tissue of a subject and a step for comparing the Largen expression level in the kidney cancer tissue of the subject with a control; and a method of screening an anti-kidney cancer substance, said method comprising (1) a step for contacting a test substance with kidney cancer cells that express Largen, (2) a step for measuring the expression amount of Largen in the kidney cancer cells, and (3) a step for comparing the thus determined expression amount of Largen with the expression amount of Largen in the kidney cancer cells that have not been contacted with the test substance and thus selecting a test substance that lowers the expression amount.

A combination drug for treating kidney caner, said combination drug comprising a tyrosine kinase inhibitor combined with a dipeptidyl peptidase 4 inhibitor; and a therapeutic effect enhancer for a tyrosine kinase inhibitor, said therapeutic effect enhancer comprising a dipeptidyl peptidase 4 inhibitor and enhancing the therapeutic effect of the tyrosine kinase inhibitor on kidney cancer.

The invention relates to the field of biological medicine manufacturing, in particular to a monoclonal antibody capable of being specifically combined with carbonic anhydrase IX and application of the monoclonal antibody in urinary disease treatment. The monoclonal antibody is Y03, a heavy chain variable region of the monoclonal antibody comprises CDR1 of which the amino acid sequence is shown as SEQ ID NO: 2, CDR2 of which the amino acid sequence is shown as SEQ ID NO: 3 and CDR3 of which the amino acid sequence is shown as SEQ ID NO: 4, and a light chain variable region of the monoclonal antibody comprises CDR1 of which the amino acid sequence is shown as SEQ ID NO: 6, CDR2 of which the amino acid sequence is shown as SEQ ID NO: 7 and CDR3 of which the amino acid sequence is shown as SEQ ID NO: 8. The monoclonal antibody Y03 is high in affinity and good in specificity, has potential value in treatment of urinary diseases, for example, has good killing activity on solid tumor cells such as kidney cancer cells, and can be applied to early diagnosis and targeted therapy of CAIX antigen expression tumors including kidney cancer.

The invention discloses a targeted drug for sensitizing Ilismos-copper complex induced copper death and application thereof, can sensitize copper death induced by tumor cells to Cu (II)-Elesclomol, and realizes high-efficiency and low-toxicity treatment of renal cell carcinoma in combination with a c-Met targeting technology, and particularly relates to a targeted drug for sensitizing Ilismos-copper complex induced copper death and application thereof. According to the targeted drug for sensitizing the ilisterim-copper complex to induce copper death, mesoporous silica serves as a nano-carrier, the surface of the carrier is modified with specific polypeptide of a targeted kidney cancer cell c-Met receptor, and taurine and a Cu (II)-Elesclomol complex are jointly loaded in an internal pore channel of the carrier.

The invention discloses a kidney cancer targeted nano tablet based on traditional Chinese medicine active ingredients and a preparation method thereof, the kidney cancer targeted nano tablet is characterized by comprising a spleen and kidney tonifying component, a yin nourishing and yang suppressing component, a blood circulation promoting and stasis removing component, a heat clearing and detoxifying component and a yang warming and qi transforming component, the raw materials are pretreated, and extracts of the medicinal materials are collected; performing nanocrystallization on the active components to obtain a nanoparticle suspension with uniform particle size; modifying with a targeting ligand to obtain a functionalized nanoparticle suspension; preparing a tablet core by taking microcrystalline cellulose as a framework material and hydroxypropyl methyl cellulose as an adhesive and adopting a direct tabletting method; performing three-layer coating by adopting an efficient coating pan; and through quality detection and packaging, the product stability and medication safety are ensured. The kidney cancer treatment nano-tablet integrates the multi-target effect of traditional Chinese medicine and the targeting delivery advantage of modern nanotechnology, a targeting pathway is constructed through special auxiliary materials and channel guiding drugs, enrichment of the drugs in kidney cancer tissue is improved, and the treatment effect is enhanced.

The invention discloses a biomarker composition for predicting the curative effect of kidney cancer immunotherapy and application of the biomarker composition. The biomarker combination comprises at least one of the following genes: MARCO, AUP1, ARHGAP42, NUP62, ADCY5 and S100A6. The biomarker combination comprises at least one of MARCO, AUP1, ARHGAP42, NUP62, ADCY5 and S100A6. The invention also provides application of a reagent for detecting the combination in preparation of a prediction or diagnosis product, a kit containing the corresponding detection reagent, and an immunotherapy drug resistance risk scoring model based on the combination. The model calculates a risk index through a specific equation. In addition, the invention also relates to an electronic device and a storage medium for realizing the model. The marker combination and the model can effectively distinguish the response of a kidney cancer patient to immunotherapy, provide a basis for an individualized treatment strategy, and have the advantages of high prediction accuracy and great clinical application potential.

The invention discloses a biomarker for monitoring kidney cancer immunotherapy responsiveness, a kit and application, and relates to the technical field of biomedicine. The invention provides a biomarker combination for monitoring the treatment responsiveness of a kidney cancer patient to an immune checkpoint inhibitor. The biomarker combination comprises CDH4 and HAVCR1; detecting the expression level or expression quantity of CDH4 and HAVCR1 in a sample to be detected, and monitoring the responsiveness of the kidney cancer patient to the treatment of the immune checkpoint inhibitor. Starting from the nature of tumor cell heterogeneity, the CDH4 + HAVCR1 + tumor cell subpopulation closely related to immunotherapy drug resistance is identified through a single cell sequencing technology, and a monitoring system developed based on the CDH4 + HAVCR1 + tumor cell subpopulation shows high accuracy in a verification queue and is superior to indexes such as traditional PD-L1 expression. A serological detection method based on peripheral blood is innovatively developed, serum detection has the advantages of being noninvasive, convenient and fast and capable of achieving dynamic monitoring, and the method is easier to popularize clinically and applied to rapid evaluation in treatment.